BostonGene, a trailblazer in the field of ai-driven molecular and immune profiling solutions, has triumphantly secured four prestigious accolades at the Clinical Trials Arena Excellence Awards. This recognition comes in the categories of Business Expansion, Innovation, and Product Launches, highlighting the company’s unwavering commitment to advancing precision diagnostics and enhancing patient outcomes.
GlobalData’s acknowledgement
The Clinical Trials Arena Excellence Awards, presented by GlobalData, celebrated BostonGene’s remarkable achievements amidst a sea of competition. With its extensive expertise in comprehensive analysis derived from researchers, journalists, and artificial intelligence, GlobalData commended BostonGene’s significant contributions to personalized therapies and improved patient care.
Recognition in the Innovation sector
BostonGene earned two awards in the Innovation category, further cementing its reputation as a pioneer in molecular diagnostics. GlobalData acknowledged BostonGene’s groundbreaking work for its Kassandra™ machine learning algorithm, which revolutionizes bulk RNA-seq cell type deconvolution. Additionally, BostonGene’s ai-driven clinical trial-matching algorithm was recognized for its transformative impact on drug development and treatment selection.
The Impactful Product Launches award
BostonGene’s Product Launches award attests to the development of a new Liquid Biopsy assay, an essential test capable of detecting clinically actionable gene alterations. With CLIA-certification and CAP-accreditation, this assay plays a vital role in predicting treatment response and monitoring disease progression. Empowering clinicians with valuable data, it facilitates customized treatment strategies for individual patients.
Expansion and Growth
BostonGene’s Business Expansion award recognizes its recent launch of CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics solutions. These platforms, coupled with the Tumor Portrait™ next-generation sequencing-based test, provide a holistic perspective of each patient’s disease profile. By offering comprehensive solutions across discovery, translational, and clinical domains, BostonGene is spearheading precision oncology efforts.
Andrew Feinberg’s perspective
President and CEO of BostonGene, Andrew Feinberg, expressed profound gratitude for the recognition received from GlobalData. He emphasized that these awards not only acknowledge past accomplishments but also signify BostonGene’s ongoing momentum in leveraging ai-driven technologies to fuel innovation in precision medicine.
BostonGene is dedicated to delivering transformative, ai-integrated molecular analytics and biomarker discovery. Through its concierge-service model, the company prioritizes customized solutions focused on real–world impact. By optimizing standard-of-care therapies and accelerating research efforts, BostonGene offers personalized roadmaps for therapeutic decision-making that encompass analyses of the immune microenvironment, actionable mutations, biomarkers, and recommended therapies.
BostonGene’s triumph at the Clinical Trials Arena Excellence Awards underscores its commitment to revolutionizing precision diagnostics and improving patient outcomes through innovative technology, impactful product launches, and strategic business expansion.
